Olink : J.P. Morgan Presentation

Disclaimer

This presentation may contain certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about: our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and our needs for additional financing, our commercial launch plans, our strategic plans for our business and products, market acceptance of our products, our competitive position and developments and projections relating to our competitors, domestic and foreign regulatory approvals, third-party manufacturers and suppliers, our intellectual property, the potential effects of government regulation and local, regional and national and international economic conditions and events affecting our business. We cannot assure that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

The forward-looking statements and opinions contained in this presentation are based on our management's beliefs and assumptions and are based upon information currently available to our management as of the date of this presentation and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Actual results, performance or events may differ materially from those in such statements due to, without limitation, risks generally associated with product development, including delays or challenges that may arise in the development, launch or scaling of our new products, programs or services, challenges in the commercialization of our products and services, the risk that we may not maintain our existing relationships with suppliers or enter into new ones, or that we will not realize the intended benefits from such relationships, any inability to protect our intellectual property effectively, changes in general economic conditions, in particular economic conditions in the markets on which we operate, changes affecting interest rate levels, changes affecting currency exchange rates, changes in competition levels, and changes in laws and regulations, and other risks described under the caption "Risk Factors" in our Registration Statement on Form F-1 (File No. 333-257842) and other documents we file with the Securities and Exchange Commission from time to time. The information, opinions and forward-looking statements contained in this announcement speak only as of its date, and are subject to change without notice and we undertake no obligation to update any such forward-looking statements for any reason, except as required by law.

This presentation contains estimates, projections and other information concerning our industry, our business, and the markets for our products and services. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.

2

Uniquely addressed all challenges in proteomics - highest data quality

Sensitivity

Specificity

Dynamic range

Sample consumption

Throughput

Cost

3

Proven execution, delivering on all strategic leversin 2021

	Uppsala
Boston	Tokyo
	Shanghai

Singapore

75-	$94.5-	60%	~35%	~2x	100%	56k
76%	95.0	UKBB
Year on year revenue	FY21 $m revenues	Explore revenues as %	Q4 reagent kit share of	Team expansion in	Coverage of the	Samples delivered in
(unaudited)
growth in FY21	2021 to 416	plasma proteome	H2 2021 to the UKBB
Revenue guidance -	of total revenues FY21	revenues
(unaudited)	employees	using Explore 3072	consortia
$90-92 for FY21

Strong execution of externalizations withsignificant headroom to grow

13	15	17
		Boston
Americas

17
11	Uppsala
5
EMEA

	8
	6
	Tokyo
1	Shanghai
	APAC

Singapore

Explore labs

Signature labs

Biomark Core Labs

25	~$750k	500k		~65%		~40%	40	28

Explore customer	Explore LTM pull-	Samplepotential on	Explore revenues	Explore Kit revenues	Olink Biomark core	Signature placements
share of Q4 Explore
installations (NovaSeq)	through	Exploreexternalization	share of Q4 revenues	labs	in Q4 2021
revenues